| Revenue Growth | Total revenue $619M, down 12%; China down 45%; Labs ex-China up 4%. |
|---|---|
| Mgmt Confidence | Cautious on China and respiratory; confident in $80M structural cost savings. |
| Demand Visibility | China destocking accelerated; respiratory testing remains lower than historical norms. |
| Margin Trends | Adjusted gross margin 47.8%, down 90 bps; EBITDA margin 24%. |
| Op. Leverage | Restructuring to deliver $80M savings; OpEx declined 3% to $210M. |
| Pricing Power | China pricing pressured by nationwide IVD guidelines and lower reimbursement rates. |
| Vol vs Price | Growth driven by ex-China volume; China hit by price and volume. |
| Segment Growth | Labs and Immunohematology grew low-to-mid single digits excluding China. |
| Capex & Debt | Net debt $2.8B; leverage 4.5x; CapEx reduced to $19M from $49M. |
| Regulatory | China nationwide IVD pricing guidelines impacting provincial implementation and reimbursement. |
| Commentary | Evolving from regional to business-unit model: Core Diagnostics and Point of Care. |
| New Launches | Expanding Vitros 450 launch; building manufacturing for Sofia and Lexa platforms. |
Growth
Total revenue declined 12% constant currency; Labs grew 4% and Immunohematology 3% excluding China.
Outlook
Targeting $80 million annual savings by 2027; China revenue expected to drop to 4-5% in 2027.
Risks
China revenue fell 45%; management pivoted on specific asset sale rumors while prioritizing deleveraging.
The company's earnings call, NASDAQ: QDEL, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
QuidelOrtho Corp: key numbers
- Share price
- $10.21Close, Nov 16
- Market cap
- $701M
- Shares outstanding
- 68.61MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from QuidelOrtho Corp
All →QuidelOrtho Q3 2026 Results: Net Loss of $53.8M, Loss Narrows
QuidelOrtho reported a net loss of $53.8 million for the third quarter of 2026, a significant improvement from the $733.0 million loss in the prior year which was driven by a large goodwill impairment. Total revenues decreased to $618.9 million from $699.9 million year-over-year, while the company's accumulated deficit grew to $1,234.5 million.
- Key figure
- Net loss $53.8M
QuidelOrtho Financial Results
QuidelOrtho reported Q3 2026 revenue of $619 million, a 12% decrease year-over-year primarily due to lower sales in China and a softer respiratory season. The company also announced a major cost transformation and restructuring program expected to deliver over $80 million in annual savings by 2027, involving a shift to two focused business units: Core Diagnostics and Point of Care Diagnostics.
- Term
- Q3 2026
“The underlying performance of our Labs and Immunohematology businesses remained solid in the third quarter, supported by the strength and durability of our customer relationships and our large global installed base. While China and a softer respiratory season continue to pressure our results, we are taking decisive action to strengthen the Company through a new cost transformation and enterprise restructuring program.”
Brian J. Blaser, President and Chief Executive Officer
QuidelOrtho $3.4B Debt Financing with Bank of America, N.A.
QuidelOrtho Corporation entered into an amendment to its existing credit agreement to reset financial covenant levels through September 30, 2029, providing a 'Covenant Relief Period' with adjusted leverage and interest coverage ratios. The underlying $3.4 billion financing package includes a $1.15 billion Term Loan A, a $100 million delayed draw facility, a $1.45 billion Term Loan B, and a $700 million revolving credit facility.
- Value
- $3.4B
- Counterparty
- Bank of America, N.A.
- Term
- through Sep 2029